4DMedical Ltd (AU:4DX)
ASX:4DX
Want to see AU:4DX full AI Analyst Report?
4DX Stock Chart & Stats
AU$5.84
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$5.84
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$7.55
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$2.39B
Enterprise ValueAU$2.30B
Total Cash (Recent Filing)AU$56.76M
Total Debt (Recent Filing)AU$6.42M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Aug 27, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding595,097,660
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.97Price Target Upside-14.95% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.37
Revenue Forecast (FY)AU$7.00M
Bulls Say, Bears Say
Bulls Say
Proprietary XV Imaging Platform4DMedical’s XV imaging and XV Lung Ventilation Analysis platform is a specialized, clinically focused product offering. A durable, proprietary imaging analytics solution entrenches the company in clinical workflows and creates a structural advantage versus generalist imaging vendors if adoption steadily expands.
Conservative LeverageThe company’s low debt-to-equity indicates conservative leverage, providing financial flexibility during ongoing losses and cash burn. This reduces near-term insolvency risk and preserves optionality for strategic investments or orderly capital raises without excessive interest burden.
High Gross Profit MarginA high gross profit margin suggests the core XV technology benefits from scalable, asset-light economics (software/analytics). If revenue stabilises and fixed costs are leveraged, this structural margin can drive sustainable gross-to-operating profit conversion over a medium-term horizon.
Bears Say
Declining RevenueRevenue contraction indicates demand or commercial execution challenges for the XV platform. Persistent top-line decline limits the company’s ability to cover fixed costs and achieve operating leverage, extending the timeline to profitability and weakening the business case for further scaling.
Negative Operating And Free Cash FlowSustained negative operating and free cash flows create structural liquidity pressure, forcing reliance on external financing. Over months this elevates dilution or refinancing risk, reduces ability to fund commercial expansion, and constrains strategic investment in clinical adoption.
Persistent Losses And Negative ROEMaterial and ongoing net losses with negative ROE signal the company is not yet generating shareholder returns. This limits retained-capital funding for R&D and commercialization, likely requiring external capital and creating execution risk that can slow long-term scaling.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$7.55 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$2.39B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 78 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.259 earnings per share for the quarter, missing the consensus estimate of -AU$0.036 by -AU$0.223.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 595,097,660 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.259 in its last earnings report, missing expectations of -AU$0.036. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$4.97 (-14.95% Downside)
AU$4.97 (-14.95% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 93%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-890.76%
Trailing 12-Months
Asset Growth
36.79%
Trailing 12-Months
Company Description
4DMedical Ltd
Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, an advanced system for four-dimensional lung imaging. Beyond this core offering, its suite of products includes a software-as-a-service (SaaS) delivery model, specialized XV lung ventilation analysis software, and Permetium—a preclinical imaging system designed to quantify regional changes in pulmonary function. Additionally, the firm provides the AccuVent 200, a ventilator tailored for small animals.
4DX Stock 12 Month Forecast
Average Price Target
AU$4.97
▼(-14.95% Downside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---